Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy

Pharmacology Research and Perspectives

Volumn 2, Issue 5, 2014, Pages

  Du, Cheng Kun ^a   Zhan, Dong Yun ^a   Morimoto, Sachio ^b   Akiyama, Tsuyoshi ^a   Schwenke, Daryl O ^c   Hosoda, Hiroshi ^a   Kangawa, Kenji ^a   Shirai, Mikiyasu ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Ghrelin; heart failure; inherited dilated cardiomyopathy; knock in mouse; sudden cardiac death; survival

Indexed keywords

ATRIAL NATRIURETIC FACTOR; GHRELIN; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE DELETION; HEART FAILURE; HEART RATE VARIABILITY; HEART VENTRICLE HYPERTROPHY; HISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SYMPATHETIC NERVE; WESTERN BLOTTING;

EID: 84992196327     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.64     Document Type: Article

References (33)

1. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. (2002). Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159: 1029–1037.
2. Date Y, Nakazato M, Murakami N, Kojima M, Kangawa K, Matsukura S (2001). Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem Biophys Res Commun 280: 904–907.
3. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. (2007). Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 101: 185–194.
4. Fatkin D, Graham RM (2002). Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82: 945–980.
5. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. (1997). Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48: 23–29.
6. Hanson EL, Jakobs PM, Keegan H, Coates K, Bousman S, Dienel NH, et al. (2002). Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy. J Card Fail 8: 28–32.
7. Iglesias MJ, Pineiro R, Blanco M, Gallego R, Dieguez C, Gualillo O, et al. (2004). Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 62: 481–488.
8. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, et al. (2000). Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343: 1688–1696.
9. 2+ channel blockade prevents sudden death in mice with heart failure. Circulation 120: 743–752.
10. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656–660.
11. Komajda M, Charron P (2002). Idiopathic cardiomyopathies. Rev Prat 52: 1664–1670.
12. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K (2004). Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109: 120–124.
13. Li L, Morimoto S, Take S, Zhan DY, Du CK, Wang YY, et al. (2012). Role of brain serotonin dysfunction in the pathophysiology of congestive heart failure. J Mol Cell Cardiol 53: 760–767.
14. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M (2004). Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 43: 977–982.
15. Mao Y, Tokudome T, Otani K, Kishimoto I, Nakanishi M, Hosoda H, et al. (2012). Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves. Endocrinology 153: 3426–3434.
16. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M (2002). Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 40: 694–699.
17. Mohan SB, Parker M, Wehbi M, Douglass P (2002). Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure. Cleve Clin J Med 69: 481–487.
18. Morimoto S (2008). Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res 77: 659–666.
19. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. (2001). Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104: 1430–1435.
20. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. (2004). Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110: 3674–3679.
21. Nakaura H, Morimoto S, Yanaga F, Nakata M, Nishi H, Imaizumi T, et al. (1999). Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy. Am J Physiol 277: C225–C232.
22. Perrot A, Ranke MB, Dietz R, Osterziel KJ (2001). Growth hormone treatment in dilated cardiomyopathy. J Card Surg 6: 127–131.
23. Pulman KJ, Fry WM, Cottrell GT, Ferguson AV (2006). The subfornical organ: a central target for circulating feeding signals. J Neurosci 26: 2022–2030.
24. Schwenke DO, Tokudome T, Kishimoto I, Horio T, Shirai M, Cragg PA, et al. (2008). Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology 149: 5172–5176.
25. Schwenke DO, Tokudome T, Kishimoto I, Horio T, Cragg PA, Shirai M, et al. (2012). One Dose of ghrelin prevents the acute and sustained increase in cardiac sympathetic tone after myocardial infarction. Endocrinology 153(5): 2436–2443.
26. Shimizu S, Akiyama T, Kawada T, Sonobe T, Kamiya A, Shishido T, et al. (2011). Centrally administered ghrelin activates cardiac vagal nerve in anesthetized rabbits. Auton Neurosci 162: 60–65.
27. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, et al. (2008). Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294: H426–H432.
28. Sutton MG, Sharpe N (2000). Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101: 2981–2988.
29. Thayer JF, Yamamoto SS, Brosschot JF (2010). The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 141: 122–131.
30. Thireau J, Zhang BL, Poisson D, Babuty D (2008). Heart rate variability in mice: a theoretical and practical guide. Exp Physiol 93: 83–94.
31. Udelson JE, Patten RD, Konstam MA (2003). New concepts in post-infarction ventricular remodeling. Rev Cardiovasc Med 4: S3–S12.
32. Zhan DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A, et al. (2009). Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. Cardiovasc Res 84: 64–71.
33. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK (2006). Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 494: 528–548.